Emerging Biomarkers in Combination Therapy: Advancing Immunotherapy Strategies for Lung Cancer

Emerging Biomarkers in Combination Therapy: Advancing Immunotherapy Strategies for Lung Cancer

2025.02.26
Immuno-oncology (IO) has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), providing durable responses and survival benefits across different disease stages. The success of immune checkpoint inhibitors (ICIs), including PD-(L)1 and CTLA-4 inhibitors, has paved the way for dual immune checkpoint blockade (ICB) therapy, aiming to enhance antitumor immunity. While clinical trials such as KEYNOTE-024 and KEYNOTE-189 have demonstrated significant benefits with ICI monotherapy or ICI combined with chemotherapy in advanced NSCLC, overcoming treatment resistance and improving five-year overall survival (OS) remain key challenges.
Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine

Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine

2025.02.26
Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine. This large-scale, nationwide cohort study across Denmark, Finland, Norway, and Sweden found that children who received MMR after the diphtheria-tetanus-acellular pertussis (DTaP) vaccine had lower rates of infectious disease hospitalizations, suggesting potential non-specific protective effects beyond its targeted diseases.
Annual Review | Dr. Ou Bai: Focusing on Advances and Challenges in PTCL Diagnosis and Treatment in 2024

Annual Review | Dr. Ou Bai: Focusing on Advances and Challenges in PTCL Diagnosis and Treatment in 2024

2025.02.25
In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the diagnosis and treatment of peripheral T-cell lymphoma (PTCL) in 2024. Dr. Ou Bai shared the groundbreaking advancements in PTCL treatment this year, provided insights into the innovative explorations at their hospital, and offered a forward-looking perspective on new methods and drugs in PTCL therapy.
Dr. Zhanhong Chen: Exploring New Treatment Pathways for HR+ Advanced Breast Cancer – The Future Role of CDK4/6 Inhibitors and Novel Targeted Therapies

Dr. Zhanhong Chen: Exploring New Treatment Pathways for HR+ Advanced Breast Cancer – The Future Role of CDK4/6 Inhibitors and Novel Targeted Therapies

2025.02.25
In the evolving landscape of breast cancer treatment, the management of HR+ advanced breast cancer remains a central focus. During the Northern China Breast Cancer Salon – Annual Progress Review, Dr. Zhanhong Chen from Zhejiang Cancer Hospital delivered an in-depth analysis on the stratified treatment approach for HR+ advanced breast cancer. Following the meeting, Oncology Frontier invited Professor Chen to discuss key topics, including the optimal timing for CDK4/6 inhibitor use and the future development of novel targeted therapies.